Core Viewpoint - Heptagon Pharmaceuticals-B (02142) saw a nearly 5% increase in stock price, reaching a new high of 17.98 HKD, following the completion of a share placement and significant investment from the Singapore Government Investment Corporation (GIC) [1] Group 1: Share Placement and Financials - The company announced the completion of a share placement of 45.022 million new shares, raising a net amount of 512 million HKD [1] - Approximately 50% of the funds will be allocated to the development of innovative drug assets, around 40% for advancing existing pipeline drug assets in clinical trials, and about 10% for working capital and other general corporate purposes [1] Group 2: Investment by GIC - On August 29, GIC increased its stake in Heptagon Pharmaceuticals by acquiring 40.222 million ordinary shares at an average price of 12.7133 HKD per share, totaling approximately 511 million HKD [1] - Following this acquisition, GIC's total shareholding rose to 53.977 million shares, increasing its ownership percentage from 1.62% to 6.37% [1]
和铂医药-B涨近5%创新高 公司宣布完成配售事项 GIC增持后持股比例已超6%